Stay updated on Idarubicin, Cytarabine, Nivolumab in MDS/AML Clinical Trial
Sign up to get notified when there's something new on the Idarubicin, Cytarabine, Nivolumab in MDS/AML Clinical Trial page.

Latest updates to the Idarubicin, Cytarabine, Nivolumab in MDS/AML Clinical Trial page
- Check6 days agoChange DetectedRevision tag updated from v3.4.2 to v3.4.3. No user-facing content appears to be changed.SummaryDifference0.0%

- Check13 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check34 days agoChange DetectedRevision: v3.4.2 is now shown. The previously displayed notices about government funding lapse (v3.4.1) have been removed.SummaryDifference0.3%

- Check41 days agoChange DetectedThe page now shows an administrative notice about a lapse in government funding and an updated revision tag (v3.4.1) replacing v3.4.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check48 days agoChange DetectedThe update adds a glossary display option and updates several page labels and revision text, for example 'Last Update Submitted that Met QC Criteria' and 'Revision: v3.4.0', while older labels like 'No FEAR Act Data' are removed.SummaryDifference0.2%

- Check62 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4; this minor version change does not affect page content or functionality. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check84 days agoChange DetectedAdded a Locations section with a Texas site; removed the Texas Locations section and the HHS Vulnerability Disclosure link, and updated the revision to v3.3.3.SummaryDifference0.2%

Stay in the know with updates to Idarubicin, Cytarabine, Nivolumab in MDS/AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Idarubicin, Cytarabine, Nivolumab in MDS/AML Clinical Trial page.